Burns Carrick, Kubicki Shelby, Nguyen Quoc-Bao, Aboul-Fettouh Nader, Wilmas Kelly M, Chen Olivia M, Doan Hung Quoc, Silapunt Sirunya, Migden Michael R
Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Dermatology, University of Texas McGovern Medical School at Houston, 6655 Travis St. Suite 700, Houston, TX 77030, USA.
Cancers (Basel). 2022 Jul 27;14(15):3653. doi: 10.3390/cancers14153653.
cSCC is increasing in prevalence due to increased lifespans and improvements in survival for conditions that increase the risk of cSCC. The absolute mortality of cSCC exceeds melanoma in the United States and approaches that of melanoma worldwide. This review presents significant changes in the management of cSCC, focusing on improvements in risk stratification, new treatment options, optimization of existing treatments, and prevention strategies. One major breakthrough in cSCC treatment is the advent of immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), which have ushered in a renaissance in the treatment of patients with locally advanced and metastatic disease. These agents have offered patients with advanced disease decreased therapeutic toxicity compared to traditional chemotherapy agents, a more durable response after discontinuation, and improved survival. cSCC is an active field of research, and this review will highlight some of the novel and more developed clinical trials that are likely to impact cSCC management in the near future.
由于寿命延长以及增加皮肤鳞状细胞癌（cSCC）风险的疾病的生存率提高，cSCC的患病率正在上升。在美国，cSCC的绝对死亡率超过黑色素瘤，在全球范围内接近黑色素瘤的死亡率。本综述介绍了cSCC管理方面的重大变化，重点关注风险分层的改进、新的治疗选择、现有治疗的优化以及预防策略。cSCC治疗的一项重大突破是靶向程序性细胞死亡蛋白1（PD-1）和程序性死亡配体1（PD-L1）的免疫检查点抑制剂（ICI）的出现，这为局部晚期和转移性疾病患者的治疗带来了复兴。与传统化疗药物相比，这些药物为晚期疾病患者降低了治疗毒性，停药后反应更持久，并提高了生存率。cSCC是一个活跃的研究领域，本综述将重点介绍一些可能在不久的将来影响cSCC管理的新颖且更成熟的临床试验。
